Want to see TWST full AI Analyst Report?
TWST Stock Chart & Stats
$90.27
-$2.17(-2.35%)
At close: 4:00 PM EDT
$90.27
-$2.17(-2.35%)
Day’s Range― - ―
52-Week Range$23.30 - $145.93
Previous CloseN/A
Volume1.05M
Average Volume (3M)1.79M
Market Cap
$9.58B
Enterprise Value$6.35K
Total Cash (Recent Filing)$166.84M
Total Debt (Recent Filing)$93.59M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Nov 13, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding65,832,420
10 Day Avg. Volume1,142,308
30 Day Avg. Volume1,792,237
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$112.00Price Target Upside24.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.1
Revenue Forecast (FY)$456.32M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Margin ExpansionSustained double-digit growth alongside improving gross margins indicates rising product adoption and better economics. Continued revenue scale can increase operating leverage and support Twist’s longer-term path toward profitability.
Manufacturing Efficiency And CapacityThese operational improvements strengthen Twist’s competitive position by lowering unit costs, increasing throughput, and improving customer service. Greater capacity and efficiency should support scalable growth while helping sustain or expand gross margins.
AI-Enabled Protein Design PositioningThe engagement validates Twist’s role in connecting computational protein design with laboratory production and testing. As AI-driven discovery expands, this capability may create recurring demand from developers needing high-throughput biological validation.
Bears Say
Persistent Losses And Cash BurnTwist remains dependent on external funding while its operations consume cash and generate substantial losses. Until revenue growth converts into durable positive operating cash flow, financial flexibility and shareholder returns remain constrained.
High Operating Expenses Delay ProfitabilityElevated spending continues to offset gross-profit gains, leaving EBITDA breakeven dependent on future cost reductions and execution. Any delay in achieving operating leverage could extend losses and increase the need for additional capital.
Competitive Pricing And Mix PressureCompetition and discounting could pressure average selling prices and shift demand toward lower-margin products or services. This risk may limit the company’s ability to translate technological differentiation and volume growth into sustained margin expansion.
Twist Bioscience News
TWST FAQ
What was Twist Bioscience’s price range in the past 12 months?
Twist Bioscience lowest stock price was $23.30 and its highest was $145.93 in the past 12 months.
What is Twist Bioscience’s market cap?
Twist Bioscience’s market cap is $9.58B.
When is Twist Bioscience’s upcoming earnings report date?
Twist Bioscience’s upcoming earnings report date is Nov 13, 2026 which is in 80 days.
How were Twist Bioscience’s earnings last quarter?
Twist Bioscience released its earnings results on Aug 03, 2026. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.506 by -$0.054.
Is Twist Bioscience overvalued?
According to Wall Street analysts Twist Bioscience’s price is currently Undervalued.
Does Twist Bioscience pay dividends?
Twist Bioscience does not currently pay dividends.
What is Twist Bioscience’s EPS estimate?
Twist Bioscience’s EPS estimate is -0.4.
How many shares outstanding does Twist Bioscience have?
Twist Bioscience has 65,832,420 shares outstanding.
What happened to Twist Bioscience’s price movement after its last earnings report?
Twist Bioscience reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.506. Following the earnings report the stock price went up 10.388%.
Which hedge fund is a major shareholder of Twist Bioscience?
Currently, no hedge funds are holding shares in TWST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Twist Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$112.00 (24.07% Upside)
$112.00 (24.07% Upside)
Blogger Sentiment
Neutral
TWST Sentiment 70%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.48%
Trailing 12-Months
Company Description
Twist Bioscience
Twist Bioscience Corporation (TWST) is a synthetic biology and life-sciences company that designs and manufactures synthetic DNA at scale. It serves customers across biotechnology, pharmaceutical research and development, academic and government labs, and applied markets, leveraging a silicon-based DNA synthesis platform to produce products such as custom DNA (including genes and fragments), oligonucleotide pools, NGS target enrichment tools, and antibody discovery/engineering reagents and services (including antibody libraries).
TWST Company Deck
TWST Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and commercial narrative: record revenue ($118.4M, +23% YoY), strong DSPS and therapeutics growth (+39% and +49% YoY respectively), improved gross margin (52.8%, +120 bps sequential), operational efficiency gains, and raised full-year guidance. Management reiterated confidence in triple-digit AI-enabled order growth for FY2026 and FY2027 and guided to adjusted EBITDA breakeven in Q4. Near-term risks include a Q3 adjusted EBITDA loss (~$11.3M), elevated OpEx, modest cash decline, some underperforming segments, and timing/visibility risks around order-to-revenue conversion and competitive dynamics. Overall, positive momentum and structural improvements outweigh the near-term profitability and timing challenges.View all TWST earnings summariesTWST Stock 12 Month Forecast
Average Price Target
$112.00
▲(24.07% Upside)
Technical Analysis
Ownership Overview
2.54% Insiders
25.77% Mutual Funds
43.76% Other Institutional Investors
3.20% Public Companies and
Individual Investors